Basal Cell Carcinoma Treatment: What Patients Need to Know. Basal cell carcinoma (BCC) is the most common type of skin cancer. The good news is important: most basal cell carcinomas are highly treatable, especially when diagnosed early.
But “rarely fatal” does not mean “harmless.”
BCC usually grows slowly and rarely spreads to distant organs. However, an untreated basal cell carcinoma can continue growing into surrounding skin and eventually invade cartilage, muscle, bone or nerves. Large or recurrent tumors—particularly on the face, nose, ears and around the eyes—can become difficult to treat and potentially disfiguring.
The goal, therefore, is not simply to remove the cancer. It is to choose a treatment that provides a high probability of cure while preserving as much normal tissue, function and appearance as possible.
For many patients, that means surgery. For selected patients, however, less invasive treatments may be reasonable.
To Learn More About Basal Cell Carcinoma- click now
Have you been diagnosed with basel cell carcinoma? I am a cancer survivor and cancer coach. Scroll down the page, post a question or comment for me and I will reply to you ASAP.
David Emerson
- Cancer Survivor
- Cancer Coach
- Director PeopleBeatingCancer
Basal Cell Carcinoma at a Glance
BCC usually:
- grows slowly;
- remains localized;
- rarely metastasizes;
- is highly treatable when caught early.
However, treatment decisions depend on much more than simply having a diagnosis of BCC. Your dermatologist should consider:
- tumor location;
- tumor size;
- depth;
- histologic subtype;
- whether the borders are clearly defined;
- whether the tumor has been treated previously;
- immune status;
- age and overall health;
- cosmetic and functional considerations.
The American Academy of Dermatology emphasizes risk stratification because not every basal cell carcinoma should be treated the same way.
Research: American Academy of Dermatology — Basal Cell Carcinoma Clinical Guideline
Is Basal Cell Carcinoma Dangerous?
Usually, BCC is considerably less dangerous than melanoma and is less likely to spread than cutaneous squamous cell carcinoma. But I don’t think patients should interpret this to mean that BCC can simply be ignored.
A basal cell carcinoma that continues growing can become locally destructive. According to the American Academy of Dermatology, advanced tumors may grow into cartilage, muscle and bone and, in rare cases, metastasize to lymph nodes, lungs, bones, liver or other locations.
Research: American Academy of Dermatology — BCC Symptoms and Treatment
The practical message is simple:
Treating a small BCC early is usually much easier than treating a large BCC later.
What Is the Best Treatment for Basal Cell Carcinoma?
There isn’t one best treatment for every patient. The National Cancer Institute lists a range of treatments for localized BCC, including:
- surgical excision;
- Mohs micrographic surgery;
- curettage and electrodesiccation;
- radiation therapy;
- cryosurgery;
- topical medications;
- photodynamic therapy.
Research: National Cancer Institute — Skin Cancer Treatment
1. Standard Surgical Excision
For many basal cell carcinomas, standard surgical excision is an excellent treatment.
The dermatologist removes the tumor along with a margin of apparently normal skin. The tissue is then examined to determine whether cancer cells extend to the surgical margins.
If the margins are clear, treatment may be complete.
Standard excision can be particularly appropriate for many primary BCCs in locations where removing an adequate margin will not cause major functional or cosmetic problems.
2. Mohs Micrographic Surgery
Mohs surgery removes the cancer layer by layer. Each layer is examined microscopically while the patient waits, allowing the surgeon to continue removing tissue specifically where cancer cells remain. This offers two important advantages:
high cure rates + preservation of healthy tissue.
Mohs can be especially valuable for BCCs that are:
- located on cosmetically or functionally important areas of the face;
- recurrent;
- large;
- poorly defined;
- aggressive histologic subtypes;
- located in areas where preserving normal tissue is particularly important.
That doesn’t mean every BCC requires Mohs. The American Academy of Dermatology specifically advises against routinely using Mohs for uncomplicated, low-risk keratinocyte cancers smaller than 1 cm on the trunk and extremities in otherwise healthy people.
Research: AAD Choosing Wisely — Appropriate Use of Mohs Surgery
For more PBC discussion of facial BCC and treatment choices, see:
Basal Cell Carcinoma on My Nose
3. Curettage and Electrodesiccation
Curettage and electrodesiccation (ED&C) involves scraping away the tumor and treating the area with an electric current. It can be effective for carefully selected low-risk BCCs, particularly small tumors on areas such as the trunk and extremities.
Advantages can include:
- quick outpatient treatment;
- no complex surgery;
- relatively low cost.
The tradeoff is that it does not provide the same microscopic margin assessment as Mohs surgery.
4. Topical Treatments
Some superficial, low-risk basal cell carcinomas can be treated with medications applied directly to the skin. Two important options are:
Imiquimod
Imiquimod stimulates an immune response against abnormal cells and is FDA-approved for certain superficial BCCs.
5-Fluorouracil (5-FU)
Topical 5-FU is another option for selected superficial BCCs.
These treatments can be attractive because they avoid surgery, but they should not automatically be viewed as substitutes for excision or Mohs: tumor subtype, depth, and location matter.
The American Academy of Dermatology notes that nonsurgical approaches generally have lower cure rates than surgical treatment and should primarily be considered for low-risk BCC or when surgery is inappropriate.
Research: AAD Basal Cell Carcinoma Treatment Guidance
Related PBC reading:
5-FU Cream and Non-Melanoma Skin Cancer
5. Radiation Therapy
Radiation can effectively treat selected basal cell carcinomas. It may be considered when:
- surgery is medically difficult;
- surgery would cause substantial functional or cosmetic problems;
- a patient cannot tolerate surgery;
- cancer remains after surgery;
- certain high-risk features warrant additional treatment.
Radiation also has disadvantages.
Treatment may require multiple visits, long-term skin changes can occur, and treatment of a recurrence within previously irradiated tissue can become more complicated. This issue deserves particular attention among cancer survivors who have already received substantial radiation exposure.
Related PBC reading:
Non-Melanoma Skin Cancer Risk Increases From Radiation
6. Photodynamic Therapy and Cryotherapy
Photodynamic therapy (PDT) and cryosurgery can be options for selected superficial or low-risk lesions. These approaches may offer cosmetic advantages for some patients, but recurrence risk and cure rates must be weighed against surgery. This is another reason why simply asking, “What is the least invasive treatment?” isn’t enough.
A better question is:
What treatment gives my particular BCC the best balance of cure rate, side effects, function, and cosmetic outcome?
What About Advanced Basal Cell Carcinoma?
Most patients with BCC will never reach this situation. But locally advanced or metastatic BCC requires a very different discussion. Modern systemic treatments include drugs that target the Hedgehog signaling pathway, including:
- vismodegib (Erivedge);
- sonidegib (Odomzo).
These medications can be used for selected patients whose BCC cannot appropriately be managed with surgery or radiation.
Another option is the PD-1 immune-checkpoint inhibitor cemiplimab (Libtayo) for appropriate advanced BCC, including certain patients previously treated with a Hedgehog pathway inhibitor or for whom such treatment isn’t appropriate.
Research: FDA — Cemiplimab for Advanced Basal Cell Carcinoma
The existence of these therapies is another reason that an old description of BCC as simply a cosmetic problem is no longer adequate.
Preventing Another Basal Cell Carcinoma
Treatment doesn’t end when the first BCC is removed. Once you’ve developed one skin cancer, you have an increased risk of developing another skin cancer—including another BCC, squamous cell carcinoma or melanoma.
The AAD recommends ongoing dermatologic follow-up after BCC treatment. AAD — Life After Basal Cell Carcinoma
Risk reduction should include:
- avoiding tanning beds;
- reducing unnecessary UV exposure;
- seeking shade;
- protective clothing and hats;
- appropriate broad-spectrum sunscreen;
- regular self-examination;
- dermatologist follow-up based on your individual risk.
And don’t ignore a lesion simply because it doesn’t look like melanoma. A BCC can appear as a pearly or shiny bump, a non-healing sore, a reddish patch, or a scar-like area or lesion that repeatedly bleeds and heals.
Related PBC reading:
Can Nutrition or Supplements Prevent BCC Recurrence?
This is an area where I think we need to distinguish between interesting laboratory evidence and clinically demonstrated prevention.
Many compounds—including curcumin, green tea polyphenols, resveratrol, and other phytochemicals—have antioxidant, anti-inflammatory or anticancer effects in laboratory studies. That is not the same thing as proving that taking these supplements prevents basal cell carcinoma in humans.
One complementary strategy has considerably stronger clinical evidence: nicotinamide, a form of vitamin B3. In the ONTRAC randomized clinical trial, 386 people at high risk for non-melanoma skin cancer received either nicotinamide 500 mg twice daily or placebo for 12 months.
During treatment, the nicotinamide group developed 23% fewer new non-melanoma skin cancers overall.
The reduction in BCC alone was approximately 20%, but that individual BCC result did not reach statistical significance. Importantly, the protective effect did not persist after nicotinamide was stopped.
Research: New England Journal of Medicine — Nicotinamide for Skin Cancer Chemoprevention
This makes nicotinamide worth discussing with a dermatologist for certain people with repeated non-melanoma skin cancers, but it should not be presented as a treatment for an existing BCC or as a replacement for sun protection and dermatologic surveillance.
Related PBC reading:
My Perspective as a Cancer Survivor
I am a long-term cancer survivor, and my previous cancer treatments have given me reasons to take skin cancer surveillance seriously.
My approach has evolved over the years. I believe nutrition, exercise, appropriate supplementation, and other evidence-based lifestyle strategies can play an important role in long-term survivorship. But when a biopsy confirms basal cell carcinoma, complementary therapies should not be used as substitutes for appropriate treatment.
BCC is usually highly curable. That is precisely why I think patients should deal with it while it is small and straightforward rather than allowing a highly treatable cancer to become a complicated one. At the same time, patients should understand their options. A small superficial BCC on the trunk and a recurrent BCC on the tip of the nose are both called “basal cell carcinoma,” but they may require very different treatments.
Questions to Ask Your Dermatologist
If you’ve been diagnosed with basal cell carcinoma, consider asking:
- Is my BCC considered low-risk or high-risk?
- What subtype did the biopsy identify?
- How large and deep is the tumor?
- Why are you recommending this particular treatment?
- Do I need Mohs surgery, or would standard excision be equally appropriate?
- What is the expected recurrence rate with each option?
- What cosmetic or functional changes should I expect?
- Are topical treatments appropriate for this tumor?
- If radiation is being considered, what are the long-term advantages and disadvantages?
- How often should I have skin examinations after treatment?
The Bottom Line
Basal cell carcinoma is usually highly treatable—but it should not be ignored.
For most BCCs, surgery remains the treatment with the strongest track record. Mohs surgery is particularly valuable for selected high-risk, recurrent or anatomically sensitive tumors, while standard excision and other approaches may be entirely appropriate for lower-risk cancers.
Topical medications, curettage and electrodesiccation, radiation, photodynamic therapy and other approaches provide additional options for selected patients.
And after treatment, prevention matters.
Protecting your skin from UV radiation, monitoring for new lesions, maintaining dermatology follow-up and—among appropriately selected high-risk patients—discussing interventions such as nicotinamide can help form a long-term skin-cancer prevention strategy.
The goal isn’t simply to treat today’s basal cell carcinoma.
It is to successfully treat the cancer while reducing the risk and burden of tomorrow’s skin cancers.
“According to the National Comprehensive Cancer Network (NCCN), the goal of treatment for basal cell carcinoma (BCC) is elimination of the tumor with maximal preservation of function and physical appearance…
In nearly all cases of BCC, the recommended treatment modality is surgery. [65, 5, 4] The surgical approach varies according to tumor size, depth, and location. Dermatologists may perform nearly all of the therapeutic options in an outpatient setting…”
